ESMO Preceptorship on NSCLC 2015

Oncology Meeting Resources

07 Jul - 08 Jul, Copenhagen, Denmark

ESMO Preceptorship on Lung Cancer

Main learning objectives for the ESMO Preceptorship on Non-Small-Cell Lung Cancer (NSCLC) 2015 included learning about best clinical practice in the management of NSCLC in the adjuvant, locally advanced and metastatic settings, understanding the importance of pathology and histoprognostic factors in the management of NSCLC and learning about the management of patients after progression, side‐effects of treatments, and the use of targeted agents in NSCLC.

Useful Links

Presenter Presentation title Session title
Jean-Yves Douillard Welcome from ESMO, objectives and scientific introduction Opening and Welcome
Enriqueta Felip Is there a place for neoadjuvant treatment? Session 1: Early and locally advanced stages
Jean-Yves Douillard State‐of‐the‐art: Standard of care for resectable NSCLC - Adjuvant chemotherapy Session 1: Early and locally advanced stages
Cecile Le Pechoux State-the-art for Locally Advanced unresectable/inoperable disease NSCLC: - Post-Operative Radiation Therapy (PORT) in resected N2 NSCLC - Update on RT/CT for unresectable NSCLC - Stereotactic RT and IMRT for inoperable NSCLC Session 1: Early and locally advanced stages
Dominique Grunenwald State‐of‐the‐art: Standard of care for resectable NSCLC - Surgical approach for resectable NSCLC Session 1: Early and locally advanced stages
Lukas Bubendorf Histopathology of NSCLC, IHC markers and pTNM classification Session 1: Early and locally advanced stages
Lamiae Amaadour Optimal management of IIIAN2 NSCLC Session 2 – case discussion
Ahmed Salem Unusual adjuvant NSCLC case Session 2 – case discussion
Tsira Kortua NSCLC locally advanced case Session 2 – case discussion
Luis Paz-Ares Maintenance treatment - Chemo maintenance or targeted agents or both? Session 3 - 1st line chemotherapy and contribution of bevacizumab
Wilfried Eberhardt -1st line chemotherapy and contribution of bevacizumab - Impact of second-line chemotherapy in unselected patients -Impact of Nintedanib in 2nd line in unselected patients Session 3 - 1st line chemotherapy and contribution of bevacizumab
Federico Cappuzzo Biomarker driven treatment of selected NSCLC: EGFR - EGFR TKI in mutant EGFR NSCLC - Mechanisms of resistance and drugs in development Session 4 - Biomarker driven treatment
Enriqueta Felip Biomarkers driven treatment of selected NSCLC: ALK EML4 - Crizotinib - Crizotinib resistance - 2nd generation drugs Session 4 - Biomarker driven treatment
Maria Barbu Stage IV squamous cell carcinoma NSCLC-case presentation Session 5 - case discussion
Milan Paul Kubelac Stage IV NSCLC with long-term progression-free survival by erlotinib treatment Session 5 - case discussion